Pollens - grasses, redtop agrostis alba - Biologic Drug Details

Summary for pollens - grasses, redtop agrostis alba

Tradenames:	1
High Confidence Patents:	0
Applicants:	5
BLAs:	5
Suppliers: see list	4

Pharmacology for pollens - grasses, redtop agrostis alba

Physiological Effect	Cell-mediated Immunity Increased Histamine Release Increased IgG Production
Established Pharmacologic Class	Non-Standardized Pollen Allergenic Extract Standardized Pollen Allergenic Extract
Chemical Structure	Allergens Pollen

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pollens - grasses, redtop agrostis alba Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pollens - grasses, redtop agrostis alba Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for pollens - grasses, redtop agrostis alba Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Pollen-Based Biologic Drugs: Grasses and Redtop Agrostis Alba

Last updated: February 19, 2026

What is the current landscape of biologic drugs derived from pollen, specifically grasses and Redtop Agrostis Alba?

Biologic drugs based on pollen, particularly grasses and Redtop Agrostis Alba, are emerging as environmental and therapeutic agents. These preparations are used primarily for allergy immunotherapy and potentially as bioactive compounds for crop protection. The market remains nascent but shows potential for expansion driven by increasing allergy prevalence and agricultural demand.

Market Size and Growth Potential

The global allergy immunotherapy market, which includes pollen-based biologics, was valued at approximately $4.3 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2030. The subset focused on pollen-derived biologics accounts for an estimated 10%, driven by increased allergy diagnoses and regulatory approvals.

In agriculture, biologic plant protection agents, including pollen-derived bio-stimulants and bio-pesticides, commanded a market size of $680 million in 2023, with projections to reach $1.2 billion by 2030 at a CAGR of 8.4%. Growth is fueled by regulatory shifts favoring environmentally benign solutions over chemical pesticides.

What are the key market driving forces?

Rising Prevalence of Allergies

Global allergy rates are rising, especially in urban environments. According to the World Allergy Organization, 30-40% of children and 20-30% of adults exhibit allergic rhinitis. These figures drive demand for immunotherapy options, including pollen-based biologics.

Regulatory Approvals and Clinical Validations

Regulatory agencies such as the FDA and EMA are increasingly approving pollen allergen extracts, including standardized biologic formulations. The approval of sublingual immunotherapy (SLIT) products has expanded accessibility.

Competitive Landscape and Innovations

Major pharmaceutical players such as AllerGenis, Stallergenes Greer, and ALK-Abelló dominate current allergy immunotherapy markets, emphasizing standardized, purified pollen extracts. Novel technologies focus on recombinant pollen proteins, synthetic peptides, and plant-based bioreactor production, aiming to improve safety and efficacy.

In agriculture, biotech firms develop bio-stimulants derived from pollen proteins to enhance crop resilience, aligning with sustainable farming initiatives.

What are the challenges constraining market growth?

Standardization and Quality Control

Variability in pollen allergen content hampers consistent manufacturing. Standardized extracts require extensive characterization, which increases R&D costs.

Regulatory Barriers

Evolving regulations demand robust clinical data, prolonging approval timelines. For agricultural applications, regulations governing bio-pesticides impose registration hurdles in multiple jurisdictions.

Public Awareness and Acceptance

Limited awareness about pollen-based biologics, especially outside allergy treatment communities, impedes market expansion.

Environmental Factors

Climate change influences pollen seasons and concentrations, complicating supply chain stability and formulation consistency.

What are the financial prospects and investment opportunities?

Segment	2023 Market Size	Estimated CAGR (2024-2030)	Key Factors
Allergy Immunotherapy	$430 million	8.2%	Rising allergy prevalence, regulatory approvals
Agricultural Bio-stimulants	$680 million	8.4%	Sustainability mandates, bio-based farming trends

Investment in research and development centers on standardization, recombinant allergen production, and delivery mechanisms. Biotech startups focusing on synthetic peptides and plant-based bioreactors exhibit high growth potential.

How are technological innovations shaping this market?

Recombinant and Synthetic Pollen Proteins

Engineered proteins enhance allergen specificity and safety profiles. Companies are developing recombinant pollen allergens with consistent potency, reducing batch variability.

Plant-Based Bioreactors

Using plants as bio-factories to produce pollen allergens reduces manufacturing costs and improves scalability. For instance, transgenic barley and tobacco lines generate allergen proteins at high yields.

Advanced Delivery Systems

Sublingual tablets, patches, and nanoparticle carriers improve patient compliance and bioavailability. These innovations impact market penetration rates.

What is the outlook for key players?

Company	Focus Area	Strategic Actions	Market Position
Stallergenes Greer	Pollen allergen extracts for SLIT	Expanding product portfolio; advancing recombinant allergen tech	Market leader in immunotherapy
ALK-Abelló	Standardized pollen extracts	Licensing new formulations; investing in novel delivery systems	Strong presence in Europe
BioBioworks	Plant-based allergen production	Developing scalable bio-reactor platforms	Emerging innovator
GreenBioTech	Pollen-derived plant bio-stimulants	Collaborating with agricultural biotech firms	Niche growth focus

Conclusion

The market for pollen-based biologic drugs, including grasses and Redtop Agrostis Alba, positions for steady growth driven by allergy treatment needs and agricultural sustainability trends. Advances in recombinant technology and plant bioengineering underpin future commercialization. Regulatory pathways and standardization remain critical hurdles.

Key Takeaways

• The allergy immunotherapy segment is sizable, with an expected CAGR of over 8%, driven by increasing allergy prevalence.
• Agricultural applications focus on eco-friendly bio-stimulants and bio-pesticides, expected to grow at similar rates.
• Innovations in recombinant allergens and plant bioreactor technologies will shape future market entrants and offerings.
• Standardization hurdles and regulatory barriers require targeted R&D and strategic partnerships.
• Market leaders are investing heavily in product pipeline expansion and delivery system improvements.

FAQs

1. How does standardization affect pollen-based biologic drugs?
Standardization ensures consistent allergen potency and safety, reduces manufacturing variability, and is essential for regulatory approval.

2. What are the primary regulatory challenges?
Regulatory agencies demand comprehensive clinical data for allergy biologics and environmental safety evaluations for agricultural bio-stimulants, prolonging approval timelines.

3. What role do biotech innovations play?
Recombinant pollen allergens and plant-based biofactories reduce costs, improve safety, and enable large-scale production, advancing market competitiveness.

4. How does climate change impact the market?
Altered pollen seasons and increased pollen counts can affect supply stability and allergen variability, influencing product formulation and availability.

5. What are the growth prospects for smaller biotech firms?
Firms focusing on recombinant technologies, synthetic peptides, and sustainable bio-stimulants have high growth potential due to innovation-driven demand and industry partnerships.

References

[1] Global Market Insights. (2023). Allergy immunotherapy market size and forecast.
[2] MarketsandMarkets. (2023). Agricultural bio-stimulants market report.
[3] World Allergy Organization. (2022). Global allergy prevalence data.
[4] U.S. Food and Drug Administration. (2023). Guidance for allergy biologic drug approval.
[5] European Medicines Agency. (2023). Regulation of plant-based bio-pesticides and bio-stimulants.